On Oct. 26, 2021, Axcella Therapeutics announced a new clinical program to investigate AXA1125 as a potential treatment for patients with Long COVID, a complex condition also known as Post COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC).

The United Kingdomﾒs Medicines and Healthcare products Regulatory Agency (MHRA) accepted a Phase 2a clinical trial authorization submission from Axcella Oct. 22, 2021.